Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Update on Phase IIb study of bomedemstat in essential thrombocythemia

Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on the findings of a Phase IIb study evaluating bomedemstat in patients with essential thrombocythemia (ET) who are resistant or intolerant to at least one standard treatment (NCT04254978). The trial showed efficacy in terms of reducing platelet count and improving symptoms, and showed that bomedemstat did not affect hemoglobin levels. In addition, the trial reported that this drug was well-tolerated. Prof. Harrison shares her excitement for further data on this agent in patients with ET, as well as for data on the efficacy of pelabresib in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra